NVO

Novo Nordisk manufactures a biologic peptide that 46 million patients inject weekly for chronic conditions that never resolve — stop taking it and the weight returns, the blood sugar deteriorates. The manufacturing process requires fermentation tanks costing billions and years to validate, creating a production moat that no generic manufacturer can simply replicate in a chemical plant. The result: 82% gross margins, 42% operating margins, and $16 billion in annual operating cash flow from a product that costs perhaps $5-10 to manufacture and sells for $200-800 per month per patient.

Mr. Market has slashed the stock 48% from its 2024 highs, pricing the business at 11.6x trailing earnings — the cheapest it has traded since the pre-GLP-1 era when revenue was stagnant and the obesity franchise did not exist. The Wegovy pill launched January 2026 at twice the uptake pace of any prior anti-obesity drug (50,000 weekly prescriptions within three weeks), Medicare obesity coverage expansion is pending, and CagriSema represents a next-generation molecule with superior efficacy data. If even 12-15% revenue growth materializes — roughly half the 2022-2024 pace — the shares re-rate from 11.6x toward 18-22x, implying 50-90% upside from earnings growth plus multiple expansion.

Revenue growth decelerated from 25% to 10% in DKK terms during 2025 while the GLP-1 market expanded 30%+, meaning Eli Lilly and emerging competitors captured two-thirds of incremental industry growth — the steepest share erosion in Novo Nordisk's modern history. The balance sheet has been transformed from fortress to leveraged: debt quintupled from DKK 27B to DKK 131B while cash evaporated from DKK 15.8B to DKK 498M, and Q3 2025 EPS of $0.71 represents a 23% intra-year decline from Q1's $0.95. Two C-suite departures — EVP of U.S. Operations and EVP of Product Strategy — alongside a new CEO and 9,000-employee restructuring create execution risk at the precise moment when the Wegovy pill launch and CagriSema submission demand flawless commercial coordination.